An experimental drug from Pfizer could benefit certain women with osteoporosis, federal advisers said Monday, despite concerns of side effects. A Food and Drug Administration panel of experts voted 9-3 that the benefits of Fablyn could outweigh its risks, including blood clots and vaginal bleeding, for some women. The FDA is not required to follow the advice of its advisers ...

Federal regulators say a drug from Pfizer and Ligand Pharmaceuticals effectively treats osteoporosis, though they are concerned about deaths, blood clots and other problems seen in company studies. The Food and Drug Administration noted Thursday that women treated with Pfizer's Fablyn were more likely to die of cancer and stroke than those taking placebo. Pfizer, the world's largest ...